TD Cowen analyst Ritu Baral downgraded Spero Therapeutics (SPRO) to Hold from Buy without a price target The firm cites a lack of clarity on catalyst timing following discontinuation of the SPR720 Phase 2 program for the downgrade. TD now sees a lack of clarity on meaningful catalyst flow for the shares.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRO:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue